MVP Holdings Inc. MVPT
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.0001
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 100
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 7
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
2Y 0.0000 (0.00%)
News
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths 
Napco Security: How The MVP Platform Secures Napco's Future 
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer 
First Horizon Recognized with a 2026 Training MVP Award by Training Magazine 
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer 
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) 
Digitalage Announces MVP Launch for Live, Creator-First Media Platform 
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer 
Firestone Partners, Matterhorn Venture Partners, and Fox Capital Partners Form Joint Venture for Atlanta Industrial Acquisition 
Mountain Valley Pipeline, LLC Files Formal Application Requesting FERC Authorization to Construct MVP Boost
Your note
Sign in to keep a note on MVPT — it syncs with the Stock Master app.